# Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

> **NCT01238991** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 53 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **BIOLOGICAL:** ACC-001
- **BIOLOGICAL:** ACC-001
- **BIOLOGICAL:** ACC-001

## Key facts

- **NCT ID:** NCT01238991
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01238991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01238991, "Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01238991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*